The highest drop is 74%
The collected insulin involves six purchasing groups: dietary human insulin, basic human insulin, premixed human insulin, dietary insulin analogues, basic insulin analogues and premixed insulin analogues. A total of 42 varieties will be selected from 1 1 enterprises, and it is estimated that more than 200 million varieties will be put into the market after collection.
This is the first time that insulin has entered the national market, and it is also the first time that biological drugs have entered the national market. The price reduction is generally higher than 40%. The bidding enterprises include 8 domestic pharmaceutical companies, namely Yifan Pharmaceutical (0020 19), Tianmai Bio, and Federal Pharmaceutical (3933). HK), tonghua dongbao (600867), Wanbang Pharmaceutical, Dongyang Guangyao (1558. HK), Li Gan Pharmaceutical (603087), Haizheng Pharmaceutical (600267), and Novo Nordisk, Lilly and Sanofi 3.
According to the bidding results, the lowest bid price of protamine-human insulin mixed injection (30R) is 17.89 yuan/piece, which is 64% lower than the highest effective declared price. Provided by Li Gan Pharmaceutical Company. The highest drop is the Beijing-protein zinc Recombinant Insulin Laifu Mixed Injection (25R) from Lilly, and the proposed price is 18.89 yuan/piece, with a drop of nearly 74%.
In terms of classification, the lowest bid price of the second-generation insulin was 22.32 yuan/piece, a decrease of 55%. The selected enterprises are all Yifan creatures. Among the three generations of insulin, the lowest bid for dietary insulin analogues and basic insulin analogues is Li Gan Pharmaceutical.
China is a country with diabetes. The data shows that there are 65.438+29 billion people with diabetes in China, accounting for 654.38+00% of the total population. However, the domestic insulin market has long been occupied by imported drugs. Minenet data show that in 2020, the sales of terminal insulin and similar drugs in public medical institutions in China will be close to 27 billion yuan, and the market share of Novo Nordisk, Sanofi and Lilly will exceed 70%. Centralized purchasing of several domestic products will change the pattern of domestic insulin market and help to increase domestic sales and market share.
All three faucets are on.
Gansu Pharmaceutical, tonghua dongbao Pharmaceutical and Federal Pharmaceutical are the three leading enterprises in insulin production in China. In this tender, all three companies got a batch of products.
Six products of Gan Pharmaceutical Company won the bid, including insulin aspart injection (dietary insulin analogue 19.98 yuan/piece, down 72%), insulin lispro injection (23.98 yuan/piece, down 60%) and insulin glargine injection (48.7 yuan/kloc-0 yuan/piece, down 63%).
Boosted by this news,1On October 26th, the share price of Li Gan Pharmaceutical once hit the daily limit of 165438+, and finally closed up by 5.92%. Gan Pharmaceutical Co., Ltd. is a leading three-generation insulin company in China and has been focusing on the field of diabetes. Successfully developed the first recombinant human insulin, long-acting and quick-acting recombinant insulin analogues independently developed by China, and took the lead in realizing large-scale production. Many products won the bid this time, and the insiders said it was not unexpected.
Tonghua dongbao is another leading insulin company. In 2020, the sales amount of recombinant human insulin injection is about 2.2 billion yuan. The company's second-generation insulin products have a high market share, and the third-generation insulin aspart was just approved for listing in June 5438+ 10 this year, so it caught the last bus of centralized procurement. However, after the result of winning the bid was announced, the trend of its share price was opposite to that of Li Gan Pharmaceutical. 165438+1plunged in the afternoon on October 26th, and finally closed down 5.56%.
Judging from the bidding results of centralized mining, there are five products to be selected in tonghua dongbao, with an average decline lower than that of Li Gan Pharmaceutical. Specifically, the available products include human insulin injection, protamine human insulin injection, protamine human insulin mixed injection (30R), insulin aspart injection and insulin glargine injection.
In addition, many products of listed companies have won the bid, including Federal Pharmaceuticals of Hong Kong stocks. Federal Pharmaceutical Co., Ltd. is one of the three major insulin companies in China. In July this year, insulin aspart and insulin aspart 30 were approved for listing. Prior to this, domestic insulin aspart was only approved by Li Gan Pharmaceutical Co., Ltd.
In this series, Federal Pharmaceuticals also has six products to choose from. In addition to the newly approved insulin aspart and insulin aspart 30, there are human insulin injection, protamine human insulin injection, protamine human insulin mixed injection (30R) and insulin glargine injection.
Yifan medicine also has three products to choose from. 165438+1On the evening of October 26th, the company announced that Yifan Pharmaceutical Co., Ltd., a wholly-owned subsidiary, participated in the sixth batch of national centralized drug procurement (insulin special supply). Among the human insulin injection products produced by BiotonS. The largest shareholder A (hereinafter referred to as "Bai Tong Company") who holds 365,438+0.65% of the company's shares, all three products (domestic sub-packaged products) declared this time are rated as Class A, and the publicity period is 165,438 438+ 10/27 to165.
Related questions and answers: Who are the listed companies that produce diabetes drugs? There are 18 listed companies in the concept of diabetes, including 6 listed companies in Shanghai Stock Exchange and 2 listed companies in Shenzhen Stock Exchange. They are: Yabao Pharmaceutical (stock code: 60035 1), Sannuo Bio (stock code: 300298), Changshan Pharmaceutical (stock code: 300255), Guizhou Bailing (stock code: 002424), tonghua dongbao (stock code: 600867) and Hong Qian Pharmaceutical. Molding Technology (stock code: 000700), Yiling Pharmaceutical (stock code: 002603), Xiangxue Pharmaceutical (stock code: 300 147), Fosun Pharma (stock code: 600 196), Baolingbao (stock code: 002286) Xilong Science (stock code: 002584), China Resources Shuanghe (stock code: 600062), Baiyun Mountain (stock code: 600332) and Hengrui Pharma (stock code: 600276). Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by defective insulin secretion or impaired biological function or both. Long-term hyperglycemia in diabetes mellitus leads to chronic damage and dysfunction of various tissues, especially eyes, kidneys, heart, blood vessels and nerves. Reference-Diabetes